The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Pharmacogenetics – five decades of therapeutic lessons from genetic diversity
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Pharmacogenomics — Drug Disposition, Drug Targets, and Side Effects
Evans, W. E., & McLeod, H. L. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020526 · Cited by 1,769
POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN
Mahgoub, A., Dring, L. G., Idle, J. R., Lancaster, R., & Smith, R. L. (1977) · The Lancet · doi:10.1016/s0140-6736(77)91430-1 · Cited by 1,183
Weinshilboum, R. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020021 · Cited by 1,031
Space-Time Relationships in Somesthetic Localization
Jones, F. N. (1956) · Science · doi:10.1126/science.124.3220.484-a · Cited by 836
Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry
Zanger, U. M., Raimundo, S., & Eichelbaum, M. (2004) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-003-0832-2 · Cited by 795
THE INCIDENCE OF ALKAPTONURIA : A STUDY IN CHEMICAL INDIVIDUALITY.
Garrod, A. (1902) · The Lancet · doi:10.1016/s0140-6736(01)41972-6 · Cited by 789
Genetic Control of Isoniazid Metabolism in Man
Evans, D. A. P., Manley, K. A., & McKusick, V. A. (1960) · BMJ · doi:10.1136/bmj.2.5197.485 · Cited by 784
De Morais, S. M., Wilkinson, G. R., Blaisdell, J., Meyer, U. A., Nakamura, K., & Goldstein, J. A. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09788-3 · Cited by 752
Self-citationCharacterization of the common genetic defect in humans deficient in debrisoquine metabolism
Gonzalez, F. J., Skodat, R. C., Kimura, S., Umeno, M., Zanger, U. M., Nebert, D. W., Gelboin, H. V., Hardwick, J. P., & Meyer, U. A. (1988) · Nature · doi:10.1038/331442a0 · Cited by 715
Self-citation(2001) · Molecular Therapy · doi:10.1006/mthe.2001.0396 · Cited by 680
Johansson, I., Lundqvist, E., Bertilsson, L., Dahl, M. L., Sjöqvist, F., & Ingelman-Sundberg, M. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.11825 · Cited by 644
Defective N-oxidation of sparteine in man: A new pharmacogenetic defect
Eichelbaum, M., Spannbrucker, N., Steincke, B., & Dengler, H. J. (1979) · European Journal of Clinical Pharmacology · doi:10.1007/bf00562059 · Cited by 632
Pharmacogenetics and adverse drug reactions
Meyer, U. A. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03167-6 · Cited by 602
Self-citationThe role of the CFP2C9-Leu 359 allelic variant in the tolbutamide polymorphism
Sullivan-Klose, T. H., Ghanayem, B. I., Bell, D. A., Zhang, Z.-Y., Kaminsky, L. S., Shenfleld, G. M., Miners, J. O., Birkett, D. J., & Goldstein, J. A. (1996) · Pharmacogenetics · doi:10.1097/00008571-199608000-00007 · Cited by 582
MOLECULAR MECHANISMS OF GENETIC POLYMORPHISMS OF DRUG METABOLISM
Meyer, U. A., & Zanger, U. M. (1997) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.37.1.269 · Cited by 549
Self-citationInduction of Drug Metabolism: The Role of Nuclear Receptors
Handschin, C., & Meyer, U. A. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.4.2 · Cited by 470
Self-citationDRUG REACTIONS, ENZYMES, AND BIOCHEMICAL GENETICS
Motulsky, A. G. (1957) · Journal of the American Medical Association · doi:10.1001/jama.1957.72980250010016 · Cited by 448
Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification
Heim, M., & Meyer, U. A. (1990) · The Lancet · doi:10.1016/0140-6736(90)92086-w · Cited by 447
Self-citationThe Relationship between Chemical Constitution and Taste
Fox, A. L. (1932) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.18.1.115 · Cited by 445
Nomenclature for N-acetyltransferases
Vatsis, K. P., Weber, W. W., Bell, D. A., Dupret, J., Evans, D. A. P., Grant, D. M., Hein, D. W., Lin, H. J., Meyer, U., Relling, M. V., et al. (1995) · Pharmacogenetics · doi:10.1097/00008571-199502000-00001 · Cited by 412
Self-citationModerne Probleme der Humangenetik
Vogel, F. (1959) · Ergebnisse der Inneren Medizin und Kinderheilkunde · doi:10.1007/978-3-642-94744-5_2 · Cited by 397
Discombe, G. (1974) · The Lancet · doi:10.1016/s0140-6736(74)91898-4 · Cited by 376
Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in man
K�pfer, A., & Preisig, R. (1984) · European Journal of Clinical Pharmacology · doi:10.1007/bf00541938 · Cited by 362
Steady-state plasma levels of nortriptyline in twins: Influence of genetic factors and drug therapy
Alexanderson, B., Price Evans, D. A., & Sjoqvist, F. (1969) · BMJ · doi:10.1136/bmj.4.5686.764 · Cited by 359
Molecular mechanism of slow acetylation of drugs and carcinogens in humans.
Blum, M., Demierre, A., Grant, D. M., Heim, M., & Meyer, U. A. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.12.5237 · Cited by 343
Self-citationKalow, W., & Staron, N. (1957) · Canadian Journal of Biochemistry and Physiology · doi:10.1139/o57-148 · Cited by 334
Distlerath, L. M., Reilly, P. E., Martin, M. V., Davis, G. G., Wilkinson, G. R., & Guengerich, F. P. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)39456-5 · Cited by 319
Goldstein, D. B., Tate, S. K., & Sisodiya, S. M. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1229 · Cited by 312
Identification of the primary gene defect at the cytochrome P450 CYP2D locus
Gough, A. C., Miles, J. S., Spurr, N. K., Moss, J. E., Gaedigk, A., Eichelbaum, M., & Wolf, C. R. (1990) · Nature · doi:10.1038/347773a0 · Cited by 302
The genetic basis of variability in drug responses
Roden, D. M., & George Jr, A. L. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd705 · Cited by 292
Kagimoto, M., Heim, M., Kagimoto, K., Zeugin, T., & Meyer, U. A. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)44890-3 · Cited by 265
Self-citationPharmacogenetics. Heredity and the Response to Drugs.
(1963) · Annals of Internal Medicine · doi:10.7326/0003-4819-58-4-757 · Cited by 242
Antibodies against human cytochrome P-450db1 in autoimmune hepatitis type II.
Zanger, U. M., Hauri, H. P., Loeper, J., Homberg, J. C., & Meyer, U. A. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.21.8256 · Cited by 238
Self-citationChou, W. H., Yan, F.-X., de Leon, J., Barnhill, J., Rogers, T., Cronin, M., Pho, M., Xiao, V., Ryder, T. B., Liu, W. W., et al. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200004000-00019 · Cited by 226
Metabolism of isoniazid in man as related to the occurrence of peripheral neuritis.
Hughes, H. B., Biehl, J., Jones, A., & Schmidt, L. H. (1954) · PubMed · doi:10.1164/art.1954.70.2.266 · Cited by 225
Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine
Bertilsson, L., Dahl, M.-L., Sjöqvist, F., Åberg-Wistedt, A., Humble, M., Johansson, I., Lundqvist, E., & Ingelman-Sundberg, M. (1993) · The Lancet · doi:10.1016/0140-6736(93)92546-6 · Cited by 223
Skoda, R. C., Gonzalez, F. J., Demierre, A., & Meyer, U. A. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.14.5240 · Cited by 195
Self-citationMendel's principles of heredity : a defence /
Bateson, W., & Mendel, G. (1902) · University Press eBooks · doi:10.5962/bhl.title.87933 · Cited by 168
Diverse point mutations in the human gene for polymorphic N-acetyltransferase.
Vatsis, K. P., Martell, K. J., & Weber, W. W. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.14.6333 · Cited by 152
Pharmacogenomics and ???Individualized Drug Therapy???
Nebert, D. W., Jorge-Nebert, L. F., & Vesell, E. S. (2003) · American Journal of PharmacoGenomics · doi:10.2165/00129785-200303060-00002 · Cited by 137
Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation
Meier, P. J., Mueller, H. K., Dick, B., & Meyer, U. (1983) · Gastroenterology · doi:10.1016/0016-5085(83)90026-4 · Cited by 123
Self-citationGarrod, A. E. (1931) · Southern Medical Journal · doi:10.1097/00007611-193106000-00028 · Cited by 113
CLINICAL EXPERIENCE WITH CHLOROTHIAZIDE
Slater, J. D., & Nabarro, J. D. N. (1958) · The Lancet · doi:10.1016/s0140-6736(58)90611-1 · Cited by 90
Decreasing smoking behaviour and risk through CYP2A6 inhibition
Sellers, E. M., Tyndale, R. F., & Fernandes, L. C. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02704-1 · Cited by 83
⃛ as consortium plans free SNP map of human genome
Masood, E. (1999) · Nature · doi:10.1038/19126 · Cited by 78
Genetic Factors in Drug Therapy: Clinical and Molecular Pharmacogenetics
Evans, P., & Dávid, A. (1994) · Cited by 67
Kahn, G. C., Boobis, A. R., Murray, S., Brodie, M. J., & Davies, D. (1982) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1982.tb01430.x · Cited by 64
Kandutsch, A. A. (1957) · Journal of Heredity · doi:10.1093/oxfordjournals.jhered.a106713 · Cited by 56
Kirchheiner, J., Bertilsson, L., Bruus, H., Wolff, A., Roots, I., & Bauer, M. (2003) · Pharmacopsychiatry · doi:10.1055/s-2003-45136 · Cited by 55
Bateson, W., Mendel, G., & Wheeler, W. M. (1902) · University Press eBooks · doi:10.5962/bhl.title.46238 · Cited by 40
Garrod's Inborn Factors in Disease
Leonard, J. V. (1990) · Journal of Medical Genetics · doi:10.1136/jmg.27.6.407-a · Cited by 39
Twin Studies in Pharmacogenetics
Vesell, E. S. (1978) · Human genetics. Supplement · doi:10.1007/978-3-642-67179-1_4 · Cited by 29
Smith, R. L. (1986) · Xenobiotica · doi:10.3109/00498258609050244 · Cited by 27
Cited by
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169
“Heritable genetic variation in drug metabolizing enzyme genes has been studied for over 60 years and many intriguing examples of the genetic influence on drug biotransformation have been investigated at great detail and for some of them clinical relevance has been studied (Meyer, 2004).”
BackgroundFunctional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation
Zanger, U. M., Turpeinen, M., Klein, K., & Schwab, M. (2008) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-008-2291-6 · Cited by 593
Preemptive Clinical Pharmacogenetics Implementation: Current Programs in Five US Medical Centers
Dunnenberger, H. M., Crews, K. R., Hoffman, J. M., Caudle, K. E., Broeckel, U., Howard, S. C., Hunkler, R. J., Klein, T. E., Evans, W. E., & Relling, M. V. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124835 · Cited by 511
Pharmacogenomics: current status and future perspectives
Pirmohamed, M. (2023) · Nature Reviews Genetics · doi:10.1038/s41576-022-00572-8 · Cited by 351
Innovations in Genomics and Big Data Analytics for Personalized Medicine and Health Care: A Review
Hassan, M., Awan, F. M., Naz, A., deAndrés-Galiana, E. J., Alvarez, O., Cernea, A., Fernández-Brillet, L., Fernández-Martínez, J. L., & Kloczkowski, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094645 · Cited by 317
“It is evident from recent advances in the pharmacological and genetic behavior of various drugs that ge-netic variations in a single individual could lead to differences in the response to drugs [28].”
Background
Metadata
- Authors
- Meyer, U. A.
- Venue
- Nature Reviews Genetics
- Published
- 2004-09
- Volume
- 5
- Issue
- 9
- Pages
- 669-676
- ISSN
- 1471-0056 (ISSN-L)
- 1471-0064
- OpenAlex
- W1605204992
- Cited by
- 420
- References
- 55
- FWCI
- 1.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.